Journal of Clinical Oncology
Articles in this Issue
The presentation of brain metastases by breast cancer subtype and potential implications for surveillance brain MRIs.
e13101 Background: As systemic therapy improves, the prevalence of breast cancer brain metastases(BCBM) is increasing. Cur...
Venous thromboembolism in gynecologic malignancies as a chronic vascular disease: A systematic review and meta-analysis of extended risk during first-line therapy in advanced epithelial ovarian cancer.
e17609 Background: Venous thromboembolism (VTE) is a frequent and clinically significant complication of gynecologic malig...
Diverging trends in head and neck cancer incidence: SEER 17 analysis of HPV-related and non–HPV-related sites, 2000–2019.
e22584 Background: Population-based evidence suggests divergent incidence patterns for head and neck squamous cell carcino...
Perioperative chemotherapy plus disitamab vedotin (RC48) and toripalimab in HER2-overexpressed locally advanced gastric or gastroesophageal junction cancer (PERISCOPE-02): An open-label, single-arm, phase 2 trial.
4080 Background: The use of Disitamab vedotin (RC48) and programmed death-1 (PD-1) inhibitor is effective in patients with...
Treatment duration with avutometinib/defactinib in recurrent low-grade serous ovarian carcinoma by KRAS mutation status.
5561 Background: Low grade serous ovarian carcinoma (LGSOC) is characterized by MAPK pathway alterations (most commonly...
Impact on overall survival after adjusting for treatment crossover in first-line metastatic NSCLC trials for pembrolizumab plus chemotherapy.
8596 Background: High crossover rates were observed in the chemotherapy alone arm in KEYNOTE(KN)-189 and KEYNOTE-407, attr...
Afatinib versus chemotherapy in advanced NSCLC with uncommon <i>EGFR</i> mutations: A pooled individual patient–level survival analysis of ACHILLES/TORG1834 and LUX-Lung 2/3/6.
e20736 Background: Uncommon EGFR mutations represent a biologically and clinically heterogeneous subset of non–small cell...
Mortality trends of lymphoid and hematopoietic malignancies among US adults: A CDC WONDER– based demographic and regional analysis, 1999–2020.
e19101 Background: Malignant neoplasms of lymphoid and hematopoietic tissues are a major cause of oncology-related morbidi...
Pulmonary hypertension-associated mortality among patients with lung cancer: A CDC WONDER analysis (2003-2023).
e20775 Background: Lung cancer remains a leading cause of cancer-related mortality globally. In advanced stages, tumor-dri...
Preoperative endocrine treatment response in primary postmenopausal endometrial cancer.
5619 Background: While preoperative endocrine therapy with letrozole has become an established approach for treatment deci...
Integrating static and dynamic modulation: An evaluation of RapidArc Dynamic for left-sided chest wall irradiation.
e12511 Background: Left-sided breast cancer radiotherapy poses a significant challenge in balancing target coverage with t...
Deconstructing implementation of reflex biomarker testing in non–small cell lung cancer (NSCLC): Diverse strategies to overcome barriers.
e13542 Background: Comprehensive tumor biomarker testing (CBT) is critical and time sensitive for newly diagnosed advanced...
Comparative burden of tumor lysis syndrome: ALL vs AML using a national U.S. dataset.
e18529 Background: Tumor lysis syndrome (TLS) is a life-threatening metabolic emergency caused by rapid tumor cell breakdo...
Age-stratified outcomes of immune checkpoint inhibitors in geriatric patients with melanoma: A real-world cohort study.
e13779 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and are used across m...
Real-world survival outcomes of patients with cholangiocarcinoma receiving chemotherapy versus chemo-immunotherapy: A TriNetX database analysis.
e16305 Background: Cholangiocarcinoma is an aggressive malignancy with poor prognosis, with median overall survival under...
Neoadjuvant tislelizumab plus chemotherapy in MSS/pMMR high-risk locally advanced colon cancer: Updated analysis results from a phase 2 trial.
3638 Background: Patients with locally advanced colon cancer (LACC) have a poor prognosis, and those with N+ or T4 staging...
Eiu-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T-cell engager, in advanced urothelial and squamous cell carcinomas.
TPS2682 Background: EVOLVE T cell engagers (TCEs) bind to a tumor antigen and to both CD3 and CD2 on T cells, thereby prov...
First-line odronextamab (Odro) plus chemotherapy (CHOP) in diffuse large B-cell lymphoma (DLBCL): OLYMPIA-3 Part 1B results.
7009 Background: Approximately 25% of patients (pts) treated with rituximab + CHOP do not have a complete response (CR), a...
Minimally invasive versus open esophagectomy for resectable esophageal cancer: Systematic review and meta-analysis of randomized controlled trials.
e16117 Background: Minimally invasive esophagectomy (MIE; thoracoscopic/robotic/hybrid) is on the rise for resectable esop...
Clinical and translational results from the phase 1 portion of the phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.
2536 Background: CHM-2101 is a Cadherin 17 directed autologous CAR T-cell product being developed to address the continuin...
Thymoma, type A, NOS: A National Cancer Database study of demographic and socioeconomic factors.
e20170 Background: Type A Thymoma (TAT), not otherwise specified (NOS), is a rare, indolent thymic epithelial tumor compos...
Integrating supervised physical activity into breast cancer survivorship care.
e24050 Background: Although the benefits of physical activity are well established, participation rates among cancer survi...
Quantitative pre-cystectomy ctDNA levels for identification of ctDNA-positive patients with surgically curable loco-regional disease versus those with occult micrometastatic progression.
4577 Background: Radical cystectomy (RC) is a life-altering operation associated with substantial morbidity. Despite its c...
Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).
e14079 Background: Treatment for recurrent GBM is limited and associated with high mortality. We hypothesize that standard...
The role of neutrophil-released myeloperoxidase in cancer-associated cachexia in patients with pancreatic cancer and in a murine cachexia model.
e24096 Background: Cancer-associated muscle wasting (i.e. cachexia) is largely driven by inflammatory mediators and affect...